| Sarah Tajudeen, | |
|
1001 W Main St Ste A, Freehold, NJ 07728-2579 | |
| (732) 637-8444 | |
| Not Available |
| Full Name | Sarah Tajudeen |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 1001 W Main St Ste A, Freehold, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093472359 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 26NJ01207600 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlas Medical Care,llc | 5597926659 | 8 |
News Archive
Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.
If President Donald Trump wins reelection next week, it seems unlikely he will unveil the health plan he's been promising since before his election in 2016. Still, other aspects of health care could be featured in his second-term agenda.
Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.
TeleHealth Services, the nation's leading provider of healthcare grade televisions and on-demand interactive patient education solutions, announced today the dates and keynote speakers for TIGRCon10, the company's annual patient education user conference. The conference, which will be focused on learning to deliver an optimal patient recovery process and improve clinical workflow, will enable hospital leadership and staff members to share best practices, discuss the role of technology in shaping the patient experience, gain new ideas and perspectives through a power user panel, and network with colleagues in the industry.
› Verified 5 days ago
| Entity Name | Atlas Medical Care,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689951592 PECOS PAC ID: 5597926659 Enrollment ID: O20120417000340 |
News Archive
Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.
If President Donald Trump wins reelection next week, it seems unlikely he will unveil the health plan he's been promising since before his election in 2016. Still, other aspects of health care could be featured in his second-term agenda.
Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.
TeleHealth Services, the nation's leading provider of healthcare grade televisions and on-demand interactive patient education solutions, announced today the dates and keynote speakers for TIGRCon10, the company's annual patient education user conference. The conference, which will be focused on learning to deliver an optimal patient recovery process and improve clinical workflow, will enable hospital leadership and staff members to share best practices, discuss the role of technology in shaping the patient experience, gain new ideas and perspectives through a power user panel, and network with colleagues in the industry.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Tajudeen, 1001 W Main St Ste A, Freehold, NJ 07728-2579 Ph: () - | Sarah Tajudeen, 1001 W Main St Ste A, Freehold, NJ 07728-2579 Ph: (732) 637-8444 |
News Archive
Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.
If President Donald Trump wins reelection next week, it seems unlikely he will unveil the health plan he's been promising since before his election in 2016. Still, other aspects of health care could be featured in his second-term agenda.
Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.
TeleHealth Services, the nation's leading provider of healthcare grade televisions and on-demand interactive patient education solutions, announced today the dates and keynote speakers for TIGRCon10, the company's annual patient education user conference. The conference, which will be focused on learning to deliver an optimal patient recovery process and improve clinical workflow, will enable hospital leadership and staff members to share best practices, discuss the role of technology in shaping the patient experience, gain new ideas and perspectives through a power user panel, and network with colleagues in the industry.
› Verified 5 days ago
Deborah A Foley, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 901 W Main St, Freehold, NJ 07728 Phone: 732-431-2000 | |
Lori Shakour, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4 Paragon Way Ste 300, Freehold, NJ 07728 Phone: 732-462-9800 | |
Jennifer Levitt, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 35 Court St Ste 1c, Freehold, NJ 07728 Phone: 609-582-4700 Fax: 279-300-3710 | |
Diane Yacono, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 901 W Main St, Freehold, NJ 07728 Phone: 732-294-2674 Fax: 732-761-8084 | |
Ms. Christine Coyle, AGACNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3499 Route 9 N, Freehold, NJ 07728 Phone: 732-370-3563 | |
Ms. Kristen Renee Beer, AGPCNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 326 Professional View Dr, Freehold, NJ 07728 Phone: 732-431-8400 | |
Rosemarie Encinas Gozum, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 77 Schanck Rd, Freehold, NJ 07728 Phone: 732-725-1415 |